Find disease awareness content and relevant supporting materials
Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment
An estimated 300 million people are affected by asthma worldwide and the burden is likely to rise substantially in the next few decades. Estimates of the prevalence of asthma range from 7% in France and Germany to 11% in the USA...
Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis
Given the relationship between allergic rhinitis (AR) and asthma, it can be hypothesized that reducing inflammation in the upper airway with intranasal corticosteroid (INCS) medications may improve asthma outcomes.
Development of New Therapies for Severe Asthma.
Persistent asthma has long been treated with inhaled corticosteroids (CSs), as the mainstay of therapy. However, their efficacy in patients with more severe disease is limited, which led to the incorporation of poor response to ICSs...
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients with Moderate to Severe Allergic Asthma not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
The primary objective of this study is to assess the therapeutic potential and safety/tolerability of QbG10 at 3 dose levels...
CHMP recommends Enerzair Breezhaler as a maintenance treatment of asthma in adult patients not adequately controlled with a combination of a long acting beta2 agonist (LABA) and a high dose of an inhaled corticosteroid.- Novartis
Novartis announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Enerzair Breezhaler (QVM 149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year.
Fostair NEXThaler 200/6
Fostair NEXThaler is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta 2 -agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta 2 -agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta 2 -agonists. Fostair NEXThaler is indicated in adults. Note: there are no relevant clinical data on the use of Fostair NEXThaler for the treatment of acute asthma attacks.